$NBP News
Last published 2d ago
- 2d agoNBPNovaBridge Biosciences to Participate in Upcoming Investor ConferencesGlobeNewswireROCKVILLE, Md., Nov. 09, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences ("NovaBridge" or the "Company") (NASDAQ:NBP) today announced that members of its leadership team will participate in two
- 2w agoNBPNovaBridge Biosciences Appoints Chuck Silberstein as Chief Financial OfficerGlobeNewswireROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences, Inc. ("NovaBridge" or the "Company") (NASDAQ:NBP) today announced the appointment of Chuck Silberstein, M.D., M.B.A. as Chief
- 2w agoNBPNovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational DevelopmentGlobeNewswireUpdated Phase 1b dataset provides nearly 18 months of median follow-up and shows the durability of clinical benefit observed with givastomigClinical activity observed across CLDN18.2 expression levels, including in
- 3w agoNBPVisara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous NeoplasiaGlobeNewswireYOL104-2 is a bioengineered, trivalent, multifunctional peptibody incorporating a core interferon-mimetic with the potential to be a first-in-class therapy for Ocular Surface Squamous Neoplasia (OSSN) Visara is a
- 4w agoNBPVisara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic KeratitisGlobeNewswireVisara secures exclusive worldwide rights, excluding Greater China, from Wuhan Hiteck Biological Pharma to develop and commercialize HT006.2.2 Visara plans to develop HT006.2.2 as VIS-102, its second clinical-stage
- 4w agoNBPHiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater ChinaPR NewswireHiteck grants Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ:NBP), exclusive worldwide rights, excluding Greater China, to develop and commercialize HT006.2.2Hiteck retains all
- 1mo agoNBPNovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026GlobeNewswireROCKVILLE, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) today announced that updated results from the Phase 1b combination study of givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB
- 2mo agoNBPTTRXNovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent DirectorGlobeNewswireMartin Dewhurst appointed as independent director and member of the Audit and Compensation CommitteesVeteran healthcare executive brings more than 30 years of leadership, governance, and strategic advisory experience
- 2mo agoNBPNovaBridge Biosciences to Participate in September Investor ConferencesGlobeNewswireROCKVILLE, Md., Aug. 27, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) ("NovaBridge" or the "Company"), a global biotechnology company that identifies differentiated innovation and
- 2mo agoNBPNovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic ExecutionGlobeNewswireExecuting NovaBridge’s strategy to identify differentiated science, develop it efficiently and create long-term value for patients and shareholdersAppointed Srishti Gupta, MD, MPP, as Chief Executive Officer, to
- 3mo agoNBPNovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026GlobeNewswireROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) ("NovaBridge" or the "Company"), a global biotechnology company that identifies differentiated innovation and
- 4mo agoNBPIVVDNovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive OfficerGlobeNewswireROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) ("NovaBridge" or the "Company"), a clinical-stage biopharmaceutical company advancing innovative medicines for
- 4mo agoNBPNovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric CancerGlobeNewswireRegistrational Phase 3 Trial Expected to Begin as Early as Q4 2026Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026 ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE) -- NovaBridge
- 5mo agoNBPJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - NOVABRIDGE BIOSCIENCESEarnings Call TranscriptsWelcome to the Jefferies Global Healthcare Conference in New York. My name is Jonah Sherl with the Jeffries Investment Making Healthcare Team. It is my pleasure to introduce Sean Fu, CEO and CMO of Philip Dennis of NovaB
- 5mo agoNBPNovaBridge to Present at the 2026 Jefferies Global Healthcare ConferenceGlobeNewswireROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that
- 6mo agoNBPNovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor ConferenceGlobeNewswireROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company), a global biotechnology platform company committed to accelerating access to innovative medicines that
- 6mo agoNBPNovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline ValueGlobeNewswireSeasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy, clinical trial design and business development discussionsStrong industry reputation and commercial track record in
- 7mo agoNBPNovaBridge Reports Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireSuccessful transformation to global biotech platform with two mid-stage potential best-in-class/first-in-class programs, givastomig and VIS-101, with compelling proof-of-concept dataGivastomig, a potential
- 8mo agoNBPNovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric CancerGlobeNewswireFDA confirmed givastomig's potential eligibility for an accelerated approval pathwayNovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective response rate (ORR) as a
- 8mo agoNBPNovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD StudyGlobeNewswireVIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitorTopline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet
- 8mo agoNBPNovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026GlobeNewswireVIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and durable treatment than the current standard of care for patients with wet AMD, DME and RVO
- 8mo agoNBPNovaBridge to Present at the Leerink Partners 2026 Global Healthcare ConferenceGlobeNewswireROCKVILLE, Md., March 02, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today
- 8mo agoNBPNovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech PlatformGlobeNewswireAppointment is a positive endorsement of NovaBridge's unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around the worldAs a
- 8mo agoNBPNovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric CancerGlobeNewswireGlobal, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and 12 mg/kg) to standard of care immunochemotherapy in patients with first line (1L) metastatic
- 9mo agoNBPNovaBridge Announces Open Market Purchases by Executive Chairman, Fu WeiGlobeNewswireROCKVILLE, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today
- 9mo agoGTBPIBRXERASCHRS+1Functional Force: Precision Platforms Disrupt the 2026 Tumor LandscapePR NewswireEquity Insider News Commentary – The precision medicine sector is undergoing a structural realignment toward platform-based biologics, as the market...
- 10mo agoNBPNovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026GlobeNewswireNovaBridge Also Included in the Highly Regarded Nasdaq Biotech Index, Emphasizing its Position as an Industry Leader Opening the first trading session of the New Year marks an excellent beginning to 2026 for
- 11mo agoNBPNovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IOGlobeNewswireRagistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar
- 11mo agoAURAFDMTNBPNovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 ForwardGlobeNewswireCadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract
- 1y agoNBPNovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian CountriesGlobeNewswireNovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet AMD, VIS-101, leveraging Everest Medicines' strong clinical and
- 1y agoNBPI-Mab Biopharma Business Update Call - NOVABRIDGE BIOSCIENCESEarnings Call TranscriptsGood day, and welcome to the IMAP Business Update Call. All participants are in a listen-only mode. After the prepared remarks, we will conduct a question-and-answer session. To ask a question, we'll ask you to press sta